Current status and future perspectives of cooperative study groups for lung cancer in Japan

Yuko Kawano, Isamu Okamoto, Haruhiko Fukuda, Yuichiro Ohe, Shinichiro Nakamura, Kazuhiko Nakagawa, Katsuyuki Hotta, Katsuyuki Kiura, Yuichi Takiguchi, Hideo Saka, Hiroaki Okamoto, Koichi Takayama, Hiroshi Semba, Kunihiko Kobayashi, Hirotsugu Kenmotsu, Masahiro Tsuboi, Nobuyuki Yamamoto, Toshihiro Nukiwa, Yoichi Nakanishi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The performance of scientifically and ethically valid prospective clinical trials is the only means by which to obtain reliable clinical evidence that can improve clinical practice and thus the outcome of patients with lung cancer. The efficacy of treatment for advanced lung cancer remains limited; many cooperative study groups for lung cancer have been established in Japan since 1990s, and they have completed several landmark investigator-initiated clinical trials. This review highlights eight active Japanese cooperative study groups for lung cancer and summarizes their achievements made through clinical trials. In addition to their benefits, the existence of multiple study groups for a single disease such as lung cancer presents several challenges including the provision of infrastructure to ensure the scientific integrity of trial results, the unnecessary duplication of effort and the wasting of limited resources, and the accrual and completion of large-scale phase III trials in the shortest possible time. Collaboration among Japanese cooperative groups has recently increased in order to overcome these challenges. Although institutional barriers to the performance of such large intergroup trials remain, further harmonization and collaboration among cooperative groups will be vital in allowing Japanese investigators to make further important contributions for the development of new lung cancer therapies.

Original languageEnglish
Pages (from-to)339-347
Number of pages9
JournalRespiratory Investigation
Volume52
Issue number6
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Lung Neoplasms
Japan
Clinical Trials
Research Personnel
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Current status and future perspectives of cooperative study groups for lung cancer in Japan. / Kawano, Yuko; Okamoto, Isamu; Fukuda, Haruhiko; Ohe, Yuichiro; Nakamura, Shinichiro; Nakagawa, Kazuhiko; Hotta, Katsuyuki; Kiura, Katsuyuki; Takiguchi, Yuichi; Saka, Hideo; Okamoto, Hiroaki; Takayama, Koichi; Semba, Hiroshi; Kobayashi, Kunihiko; Kenmotsu, Hirotsugu; Tsuboi, Masahiro; Yamamoto, Nobuyuki; Nukiwa, Toshihiro; Nakanishi, Yoichi.

In: Respiratory Investigation, Vol. 52, No. 6, 01.11.2014, p. 339-347.

Research output: Contribution to journalReview article

Kawano, Y, Okamoto, I, Fukuda, H, Ohe, Y, Nakamura, S, Nakagawa, K, Hotta, K, Kiura, K, Takiguchi, Y, Saka, H, Okamoto, H, Takayama, K, Semba, H, Kobayashi, K, Kenmotsu, H, Tsuboi, M, Yamamoto, N, Nukiwa, T & Nakanishi, Y 2014, 'Current status and future perspectives of cooperative study groups for lung cancer in Japan', Respiratory Investigation, vol. 52, no. 6, pp. 339-347. https://doi.org/10.1016/j.resinv.2014.06.004
Kawano, Yuko ; Okamoto, Isamu ; Fukuda, Haruhiko ; Ohe, Yuichiro ; Nakamura, Shinichiro ; Nakagawa, Kazuhiko ; Hotta, Katsuyuki ; Kiura, Katsuyuki ; Takiguchi, Yuichi ; Saka, Hideo ; Okamoto, Hiroaki ; Takayama, Koichi ; Semba, Hiroshi ; Kobayashi, Kunihiko ; Kenmotsu, Hirotsugu ; Tsuboi, Masahiro ; Yamamoto, Nobuyuki ; Nukiwa, Toshihiro ; Nakanishi, Yoichi. / Current status and future perspectives of cooperative study groups for lung cancer in Japan. In: Respiratory Investigation. 2014 ; Vol. 52, No. 6. pp. 339-347.
@article{77ec34b3852f466a8ac5cc5dbdf0536b,
title = "Current status and future perspectives of cooperative study groups for lung cancer in Japan",
abstract = "The performance of scientifically and ethically valid prospective clinical trials is the only means by which to obtain reliable clinical evidence that can improve clinical practice and thus the outcome of patients with lung cancer. The efficacy of treatment for advanced lung cancer remains limited; many cooperative study groups for lung cancer have been established in Japan since 1990s, and they have completed several landmark investigator-initiated clinical trials. This review highlights eight active Japanese cooperative study groups for lung cancer and summarizes their achievements made through clinical trials. In addition to their benefits, the existence of multiple study groups for a single disease such as lung cancer presents several challenges including the provision of infrastructure to ensure the scientific integrity of trial results, the unnecessary duplication of effort and the wasting of limited resources, and the accrual and completion of large-scale phase III trials in the shortest possible time. Collaboration among Japanese cooperative groups has recently increased in order to overcome these challenges. Although institutional barriers to the performance of such large intergroup trials remain, further harmonization and collaboration among cooperative groups will be vital in allowing Japanese investigators to make further important contributions for the development of new lung cancer therapies.",
author = "Yuko Kawano and Isamu Okamoto and Haruhiko Fukuda and Yuichiro Ohe and Shinichiro Nakamura and Kazuhiko Nakagawa and Katsuyuki Hotta and Katsuyuki Kiura and Yuichi Takiguchi and Hideo Saka and Hiroaki Okamoto and Koichi Takayama and Hiroshi Semba and Kunihiko Kobayashi and Hirotsugu Kenmotsu and Masahiro Tsuboi and Nobuyuki Yamamoto and Toshihiro Nukiwa and Yoichi Nakanishi",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.resinv.2014.06.004",
language = "English",
volume = "52",
pages = "339--347",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Current status and future perspectives of cooperative study groups for lung cancer in Japan

AU - Kawano, Yuko

AU - Okamoto, Isamu

AU - Fukuda, Haruhiko

AU - Ohe, Yuichiro

AU - Nakamura, Shinichiro

AU - Nakagawa, Kazuhiko

AU - Hotta, Katsuyuki

AU - Kiura, Katsuyuki

AU - Takiguchi, Yuichi

AU - Saka, Hideo

AU - Okamoto, Hiroaki

AU - Takayama, Koichi

AU - Semba, Hiroshi

AU - Kobayashi, Kunihiko

AU - Kenmotsu, Hirotsugu

AU - Tsuboi, Masahiro

AU - Yamamoto, Nobuyuki

AU - Nukiwa, Toshihiro

AU - Nakanishi, Yoichi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The performance of scientifically and ethically valid prospective clinical trials is the only means by which to obtain reliable clinical evidence that can improve clinical practice and thus the outcome of patients with lung cancer. The efficacy of treatment for advanced lung cancer remains limited; many cooperative study groups for lung cancer have been established in Japan since 1990s, and they have completed several landmark investigator-initiated clinical trials. This review highlights eight active Japanese cooperative study groups for lung cancer and summarizes their achievements made through clinical trials. In addition to their benefits, the existence of multiple study groups for a single disease such as lung cancer presents several challenges including the provision of infrastructure to ensure the scientific integrity of trial results, the unnecessary duplication of effort and the wasting of limited resources, and the accrual and completion of large-scale phase III trials in the shortest possible time. Collaboration among Japanese cooperative groups has recently increased in order to overcome these challenges. Although institutional barriers to the performance of such large intergroup trials remain, further harmonization and collaboration among cooperative groups will be vital in allowing Japanese investigators to make further important contributions for the development of new lung cancer therapies.

AB - The performance of scientifically and ethically valid prospective clinical trials is the only means by which to obtain reliable clinical evidence that can improve clinical practice and thus the outcome of patients with lung cancer. The efficacy of treatment for advanced lung cancer remains limited; many cooperative study groups for lung cancer have been established in Japan since 1990s, and they have completed several landmark investigator-initiated clinical trials. This review highlights eight active Japanese cooperative study groups for lung cancer and summarizes their achievements made through clinical trials. In addition to their benefits, the existence of multiple study groups for a single disease such as lung cancer presents several challenges including the provision of infrastructure to ensure the scientific integrity of trial results, the unnecessary duplication of effort and the wasting of limited resources, and the accrual and completion of large-scale phase III trials in the shortest possible time. Collaboration among Japanese cooperative groups has recently increased in order to overcome these challenges. Although institutional barriers to the performance of such large intergroup trials remain, further harmonization and collaboration among cooperative groups will be vital in allowing Japanese investigators to make further important contributions for the development of new lung cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=84912522002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912522002&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2014.06.004

DO - 10.1016/j.resinv.2014.06.004

M3 - Review article

VL - 52

SP - 339

EP - 347

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 6

ER -